Absence of pharmacodynamic or pharmacokinetic interactions when TAK-442, an oral, direct factor Xa inhibitor, is co-administered with aspirin or clopidogrel

被引：0
|
作者：
Stringer, Fran [1 ]
Scott, Graham [1 ]
Kupfer, Stuart [2 ]
Cao, Charlie [2 ]
Kawamura, Masaki [2 ]
机构：
[1] Takeda Global Res & Dev Inc, London, England
[2] Takeda Global Res & Dev, Deerfield, IL USA
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2010年 / 70卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：299 / 299
页数：1
相关论文
共 22 条
  • [1] PHARMACODYNAMIC INTERACTION BETWEEN TAK-442, AN ORAL DIRECT FACTOR XA INHIBITOR, AND PRASUGREL IN HEALTHY SUBJECTS
    Wood, Nolan
    Stringer, Fran
    Wu, Ruishan
    Kawamura, Masaki
    Spaeder, Jeff
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E1504 - E1504
  • [2] PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF THE NOVEL ORAL DIRECT FACTOR XA INHIBITOR TAK-442.
    Stringer, F.
    Ploeger, B.
    Scott, G.
    Kawamura, M.
    Kupfer, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S89 - S89
  • [3] The pharmacokinetics and pharmacodynamics of TAK-442, an oral, direct factor Xa inhibitor following multiple dosing in healthy male subjects
    Stringer, Fran
    Scott, Graham
    Kupfer, Stuart
    Prescott, Kim
    Jenkins, Robert
    Harding, Sarah
    Cao, Charlie
    Kawamura, Masaki
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (02) : 305 - 305
  • [4] Pharmacology of an oral factor Xa inhibitor TAK-442: Translational animal models for strategic clinical trials
    Konishi, Noriko
    Hiroe, Katsuhiko
    Kawamura, Masaki
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2010, 112 : 30P - 30P
  • [5] Antithrombotic profiles of TAK-442, a novel oral factor Xa inhibitor, in venous and arterial thrombosis models
    Konishi, N.
    Hiroe, K.
    Shinozawa, E.
    Shofuda, K.
    Matsuda, K.
    Imaeda, Y.
    Fujimoto, T.
    Kubo, K.
    Kawamura, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 759 - 760
  • [6] Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome
    Goldstein, Sidney
    Bates, Eric R.
    Bhatt, Deepak L.
    Cao, Charlie
    Holmes, David
    Kupfer, Stuart
    Martinez, Felipe
    Spaeder, Jeffrey
    Weitz, Jeffrey I.
    Ye, Zhan
    Zannad, Faiez
    THROMBOSIS AND HAEMOSTASIS, 2014, 111 (06) : 1141 - 1152
  • [7] Synergistic effect of TAK-442, a direct factor Xa inhibitor, and antiplatelet agents on whole blood coagulation and arterial thrombosis in rats
    Konishi, N.
    Hiroe, K.
    Shinozawa, E.
    Imaeda, Y.
    Kubo, K.
    Kawamura, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 384 - 385
  • [8] Effects of TAK-442, a direct factor XA inhibitor, and fondaparinux on platelet-associated prothrombinase in the balloon injured artery of rats
    Konishi, N.
    Katsuhiko, H.
    Imaeda, Y.
    Fujimoto, T.
    Kubo, K.
    Kawamura, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 759 - 759
  • [9] Effects of Fondaparinux and a Direct Factor Xa Inhibitor TAK-442 on Platelet-associated Prothrombinase in the Balloon-injured Artery of Rats
    Konishi, Noriko
    Hiroe, Katsuhiko
    Kawamura, Masaki
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2011, 57 (02) : 201 - 206
  • [10] A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery
    Weitz, Jeffrey I.
    Cao, Charlie
    Eriksson, Bengt I.
    Fisher, William
    Kupfer, Stuart
    Raskob, Gary
    Spaeder, Jeffrey
    Turpie, Alexander G. G.
    THROMBOSIS AND HAEMOSTASIS, 2010, 104 (06) : 1150 - 1157
123